EXHIBIT 99.1

 

 

Upexi Reports Revenue of $24.2 Million for Fiscal 2023 Third Quarter, an Increase of 447% Year-Over-Year

 

Clearwater, FL, May 15, 2023 (GLOBE NEWSWIRE) – Upexi, Inc. (NASDAQ: UPXI) (the “Company” or “Upexi”), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today announced its financial results for the fiscal 2023 third quarter ending March 31, 2023.

 

Fiscal 2023 Third Quarter Financial Highlights:

 

·

Revenue totaled $24.2 million, an increase of 447%, as compared to $4.4 million for the same period the prior year.

 

·

Gross profit totaled $9.6 million, an increase of 189%, as compared to $3.3 million for the same period the prior year.

 

·

Adjusted EBITDA for the quarter totaled a positive $671,339 as compared to an adjusted EBITDA loss of $877,351 for the same period in the prior year.

 

·

Net loss attributable to Upexi, Inc. shareholders was $1.6 million as compared to a net loss of approximately $0.05 million for the same period in the prior year.

 

·

Shareholder equity increased by $7.7 million to $36.1 million as compared to $28.4 million for the same period in the prior year.

 

·

Cash and cash equivalents totaled $1.2 million as of March 31, 2023. Subsequent to quarter, Upexi announced a common-only financing of $7 million.

 

“We are pleased with the organic growth of our key brands during the quarter, driving 447% quarterly year-over-year growth to $24.2 million. We increased positive Adjusted EBITDA to $671,000 for the quarter on a lower revenue base from last quarter. This is encouraging progress in a short amount of time and due to our determined optimization strategy,” stated Allan Marshall, Upexi’s Chief Executive Officer. “Management expects this trend to continue throughout the remainder of calendar 2023. We anticipate that revenue will continue to grow and that we will meet or exceed our $100 million projection, as will Adjusted EBITDA. These projections do not include recent developments such as Disney or the Non-Binding LOI issued April 13, 2023. The Company will update guidance in the future as needed as the year progresses.”

 

 Fiscal 2023 Third Quarter and Subsequent Operational Highlights:

 

·

Tytan Tiles announced a licensing agreement with The Walt Disney Company, including such key brands as Frozen, The Lion King, Toy Story, and Cars.

 

·

Tytan Tiles announced expansion from 2,200 to over 3,900 Walmart locations.

 

·

Announced agreement to acquire remaining 45% interest in Cygnet Online, one year ahead of guidance.

 

·

Consolidated third party logistics locations to improve operating efficiencies and reduce distribution costs by $1 to $1.5 million.

 

·

Signed Letter of Intent to acquire Wellness and Nutrition Brand with trailing twelve-month revenue of $15 million.

 

·

Announced $7 Million common-only financing.

 

 
1

 

 

Financial Highlights for Fiscal 2023 Third Quarter

Revenue for the three months ended March 31, 2023, totaled $24.2 million, an increase of 447% as compared to $4.4 million for the same period the year prior. The revenue growth was primarily the result of the three acquisitions and was offset from the sale of Infusionz.  Management believes that there is significant opportunity in the next 12 months for organic growth within the newly acquired business and will focus the acquisition targets on businesses that will enhance our current products or allow the business to accelerate growth.  

 

Cost of revenue during the quarter totaled $14.6 million, compared to $1.1 million for the same period the prior year. The cost of revenue growth was primarily related to the acquisition of four companies and offset with the sale of Infusionz. 

 

Gross profit for the quarter was $9.6 million, an increase of 190% as compared to $3.3 million for the same period in the prior year. Management will seek to improve the gross profit and the overall gross margin in the next 12 months as they are able to leverage the significant increase in our purchasing requirements and continue to consolidate operations. 

 

General and administrative expenses were $2.9 million, an increase of  $900,000 or 46% compared with the same period last year.   As the Company has changed with the acquisitions and the sale of Infusionz, management has managed the general and administrative costs and will continue to implement strategies to decrease the percentage of general and administrative costs when compared to total sales.  

 

The Company had a net loss from continued operations of $1.6 million for the three months ended March 31, 2023, compared to a net loss of $52,667 for the same period in the prior year. 

 

As of March 31, 2023, the Company had cash of $1.2 million, a line of credit with $4.9 million available, and stockholders’ equity attributed to Upexi stockholders of $36.1 million. On May 12, 2023, the Company announced a Registered Direct Offering of Common Stock for gross proceeds of approximately $7 million before deducting placement agent fees and other offering expenses. The closing of the offering is expected to occur on or about May 16, 2023, subject to the satisfaction of customary closing conditions. 

 

As of today, May 15, 2023 there are 18,094,748 shares of common stock outstanding.

 

Financial Results Conference Call

 

Event:

Fiscal 2023 Third Quarter Financial Results Conference Call

 

 

Date:

Monday, May 15, 2023

 

 

Time:

4:30 p.m. Eastern Time

 

 

Live Call:

1-877-300-8521 (U.S. Toll-Free) or 1-412-317-6026 (International)

 

 

Webcast:

https://viavid.webcasts.com/starthere.jsp?ei=1613123&tp_key=7d65f8a311

 

 
2

 

 

For those unable to join the conference call, a dial-in replay of the call will be available until May 29, 2023 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 10178708.

 

Additional details are available under the Investor Relations section of the Company’s website: https://upexi.com/investors.

 

About Upexi, Inc.:

Upexi is a multi-faceted brand owner with established brands in the health, wellness, pet, beauty and other growing markets. We operate in emerging industries with high growth trends and look to drive organic growth of our current brands. We focus on direct to consumer and Amazon brands that are scalable and have anticipated, high industry growth trends. Our goal is to continue to accumulate consumer data and build out a significant customer database across all industries we sell into. The growth of our current database has been key to the year over year gains in sales and profits. To drive additional growth, we have and will continue to acquire profitable Amazon and eCommerce businesses that can scale quickly and reduce costs through corporate synergies. We utilize our in-house, SaaS programmatic ad technology to help achieve a lower cost per acquisition and accumulate consumer data for increased cross-selling between our growing portfolio of brands.

 

FORWARD LOOKING STATEMENTS:

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with business strategy, potential acquisitions, revenue guidance, product development, integration and synergies of acquiring companies and personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

 

 
3

 

 

Adjusted EBITDA

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

31-Mar-23

 

 

31-Mar-22

 

Net income (Net loss) GAAP

 

$ (1,643,883 )

 

$ (52,667 )

Interest expense, net

 

$ 154,999

 

 

$ 19,705

 

Depreciation and amortization

 

$ 1,923,735

 

 

$ 351,012

 

Income Tax

 

$ (496,880 )

 

$ (1,351,686 )

Stock Compensation

 

$ 1,146,299

 

 

$ 854,013

 

Gain on sale of asset

 

$ -

 

 

$ (5,500 )

Change in derivative liability

 

$ -

 

 

$ -

 

Loss from discontinued operations

 

$ (288,127 )

 

$ (147,583 )

Loss attributable to non-controlling interest

 

$ (124,804 )

 

$ -

 

 

 

$ 671,339

 

 

$ (332,706 )

 

Company Contact

Andrew Norstrud, Chief Financial Officer

Email: andrew.norstrud@upexi.com

Phone: (702) 332-5591

 

Investor Relations Contact

KCSA Strategic Communications

Valter Pinto or Jack Perkins

Email: Upexi@KCSA.com

Phone: (212) 896-1254

 

 
4

 

 

UPEXI, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

 

 

 

Three Months Ended

March 31,

 

 

Nine Months Ended

March 31,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$ 24,219,445

 

 

$ 4,426,898

 

 

$ 62,863,128

 

 

$ 13,280,565

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of Revenue

 

 

14,614,754

 

 

 

1,098,137

 

 

 

36,904,527

 

 

 

3,081,112

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

9,604,691

 

 

 

3,328,761

 

 

 

25,958,601

 

 

 

10,199,453

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

3,476,918

 

 

 

1,085,823

 

 

 

9,210,303

 

 

 

3,821,081

 

Distribution costs

 

 

2,578,180

 

 

 

605,368

 

 

 

8,641,559

 

 

 

1,538,830

 

General and administrative expenses

 

 

2,878,255

 

 

 

1,970,276

 

 

 

8,287,779

 

 

 

6,556,627

 

Share-based compensation

 

 

1,146,299

 

 

 

854,013

 

 

 

3,126,472

 

 

 

2,333,306

 

Amortization of acquired intangible assets

 

 

1,691,243

 

 

 

236,001

 

 

 

3,534,216

 

 

 

540,836

 

Depreciation

 

 

232,492

 

 

 

115,011

 

 

 

669,540

 

 

 

361,590

 

 

 

 

12,003,387

 

 

 

4,866,492

 

 

 

33,469,869

 

 

 

15,152,270

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(2,398,696 )

 

 

(1,537,731 )

 

 

(7,511,268 )

 

 

(4,952,817 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense), net

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest (expense) income, net

 

 

(154,999 )

 

 

(19,705 )

 

 

(2,380,972 )

 

 

(61,699 )

Change in derivative liability

 

 

-

 

 

 

-

 

 

 

(1,770 )

 

 

-

 

Gain on sale of Infusionz and select assets

 

 

-

 

 

 

-

 

 

 

7,564,363

 

 

 

-

 

Gain (loss) on sale of property and equipment

 

 

-

 

 

 

5,500

 

 

 

-

 

 

 

5,500

 

Gain on SBA PPP loan extinguishment

 

 

-

 

 

 

-

 

 

 

-

 

 

 

300,995

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense), net

 

 

(154,999 )

 

 

(14,205 )

 

 

5,181,621

 

 

 

244,796

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss before income tax

 

 

(2,553,695 )

 

 

(1,551,936 )

 

 

(2,329,647 )

 

 

(4,708,021 )

Income tax benefit

 

 

496,880

 

 

 

1,351,686

 

 

 

449,828

 

 

 

1,116,653

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss from continuing operations

 

 

(2,056,815 )

 

 

(200,250 )

 

 

(1,879,819 )

 

 

(3,591,368 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss (income) from discontinued operations

 

 

288,127

 

 

 

147,583

 

 

 

(50,291 )

 

 

4,115,245

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to non-controlling interest

 

 

124,804

 

 

 

-

 

 

 

358,390

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income attributable to Upexi, Inc.

 

$ (1,643,884 )

 

$ (52,667 )

 

$ (1,571,720 )

 

$ 523,877

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic income (loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per share from continuing operations

 

$ (0.11 )

 

$ (0.01 )

 

$ (0.11 )

 

$ (0.22 )

Income (loss) per share from discontinued operations

 

$ 0.02

 

 

$ 0.01

 

 

$ (0.00 )

 

$ 0.26

 

Total (loss) income per share

 

$ (0.11 )

 

$ (0.00 )

 

$ (0.11 )

 

$ 0.03

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted (loss) income per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per share from continuing operations

 

$ (0.11 )

 

$ (0.01 )

 

$ (0.11 )

 

$ (0.20 )

Income (loss) per share from discontinued operations

 

$ 0.02

 

 

$ 0.01

 

 

$ (0.00 )

 

$ 0.23

 

Total (loss) income per share

 

$ (0.11 )

 

$ (0.00 )

 

$ (0.11 )

 

$ 0.03

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic weighted average shares outstanding

 

 

18,015,837

 

 

 

16,426,399

 

 

 

17,418,877

 

 

 

16,080,699

 

Fully diluted weighted average shares outstanding

 

 

18,015,837

 

 

 

17,821,810

 

 

 

17,418,877

 

 

 

17,586,030

 

 

 
5

 

 

UPEXI, INC.

CONDENSED CONSOLDIATED BALANCE SHEETS (UNAUDITED)

 

 

 

March 31,

 

 

June 30,

 

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Cash

 

$ 1,181,042

 

 

$ 7,149,806

 

Accounts receivable

 

 

5,346,853

 

 

 

1,137,637

 

Inventory

 

 

10,140,644

 

 

 

4,725,685

 

Due from Bloomios

 

 

1,617,216

 

 

 

-

 

Deferred tax asset, current

 

 

-

 

 

 

462,070

 

Prepaid expenses and other receivables

 

 

1,809,730

 

 

 

840,193

 

Assets of discontinued operations, net

 

 

-

 

 

 

6,449,210

 

Total current assets

 

 

20,095,485

 

 

 

20,764,601

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

7,618,148

 

 

 

7,343,783

 

Intangible assets, net

 

 

17,312,833

 

 

 

10,641,382

 

Goodwill

 

 

15,056,856

 

 

 

5,887,393

 

Deferred tax asset

 

 

2,979,918

 

 

 

2,002,759

 

Investments - Bloomios

 

 

9,955,450

 

 

 

-

 

Other assets

 

 

118,040

 

 

 

100,372

 

Right-of-use asset

 

 

678,145

 

 

 

926,570

 

Total other assets

 

 

53,719,390

 

 

 

26,902,259

 

 

 

 

 

 

 

 

 

 

Total assets

 

$ 73,814,875

 

 

$ 47,666,860

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$ 2,635,876

 

 

$ 2,018,541

 

Accrued compensation

 

 

889,634

 

 

 

531,259

 

Deferred revenue

 

 

48,162

 

 

 

105,848

 

Accrued liabilities

 

 

4,172,455

 

 

 

955,327

 

Acquisition payable

 

 

500,000

 

 

 

-

 

Current portion of notes payable

 

 

9,164,189

 

 

 

5,424,752

 

Current portion of operating lease payable

 

 

272,116

 

 

 

267,029

 

Total current liabilities

 

 

17,682,429

 

 

 

9,302,756

 

 

 

 

 

 

 

 

 

 

Operating lease payable, net of current portion

 

 

449,874

 

 

 

700,411

 

Notes payable, net of current portion

 

 

18,951,762

 

 

 

8,876,949

 

Total long-term liabilities

 

 

19,401,636

 

 

 

9,577,360

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders' equity

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value, 100,000,000 shares authorized, 500,000 and 500,000 shares issued and outstanding, respectively

 

 

500

 

 

 

500

 

Common stock, $0.001 par value, 100,000,000 shares authorized, 18,094,748 and 16,713,345 shares issued and outstanding, respectively

 

 

18,094

 

 

 

16,713

 

Additional paid in capital

 

 

44,858,392

 

 

 

34,985,597

 

Accumulated deficit

 

 

(7,842,606 )

 

 

(6,270,886 )

Total stockholders' equity attributable to Upexi, Inc.

 

 

37,034,380

 

 

 

28,731,924

 

Non-controlling interest in subsidiary

 

 

(303,570 )

 

 

54,820

 

Total stockholders' equity

 

 

36,730,810

 

 

 

28,786,744

 

 

 

 

 

 

 

 

 

 

Total liabilities and stockholders' equity

 

$ 73,814,875

 

 

$ 47,666,860

 

 

 
6